Tibet Duo Rui Pharmaceutical Co., Ltd.

SZSE:301075 Stock Report

Market Cap: CN¥1.5b

Tibet Duo Rui Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Yong Deng

Chief executive officer

CN¥640.2k

Total compensation

CEO salary percentagen/a
CEO tenure6yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure4.8yrs

Recent management updates

Recent updates

What Tibet Duo Rui Pharmaceutical Co., Ltd.'s (SZSE:301075) 41% Share Price Gain Is Not Telling You

Oct 09
What Tibet Duo Rui Pharmaceutical Co., Ltd.'s (SZSE:301075) 41% Share Price Gain Is Not Telling You

Tibet Duo Rui Pharmaceutical's (SZSE:301075) Solid Earnings May Rest On Weak Foundations

May 01
Tibet Duo Rui Pharmaceutical's (SZSE:301075) Solid Earnings May Rest On Weak Foundations

Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) Stock Rockets 44% As Investors Are Less Pessimistic Than Expected

Mar 08
Tibet Duo Rui Pharmaceutical Co.,Ltd. (SZSE:301075) Stock Rockets 44% As Investors Are Less Pessimistic Than Expected

CEO

Yong Deng (58 yo)

6yrs

Tenure

CN¥640,200

Compensation

Mr. Yong Deng serves as Chairman & GM of Tibet Duo Rui Pharmaceutical Co., Ltd. since December 2018.


Board Members

NamePositionTenureCompensationOwnership
Yong Deng
Chairman & GM6yrsCN¥640.20kno data
Fen Jin
Deputy GM & Director2.7yrsCN¥375.00kno data
Shaozhong Zhang
Vice Chairman4.8yrsCN¥525.20kno data
Qin Deng
Director7yrsCN¥120.00kno data
Fei Qi
Independent Directorno dataCN¥80.00kno data
Yingfei Liu
Independent Directorno dataCN¥80.00kno data
Hongwei Zhao
Chairman of the Supervisory Board4.6yrsno datano data
Jiali Zhou
Non-Employee Supervisor4.8yrsno datano data
Yunguo Wang
Independent Director2.7yrsCN¥80.00kno data

4.8yrs

Average Tenure

52yo

Average Age

Experienced Board: 301075's board of directors are considered experienced (4.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 06:32
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tibet Duo Rui Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution